Objective: This study aims to estimate the incidence of first hip or clinical vertebral fracture or major osteoporotic (hip, clinical vertebral, proximal humerus, or wrist) fracture in postmenopausal women undergoing their first bone mineral density (BMD) test before age 65 years.
A lthough routine bone mineral density (BMD) screening is universally recommended for women aged 65 years or older, 1<8 the optimal schedule for BMD screening in younger (aged 50-64 y) postmenopausal women is unknown. Four percent of US women aged 50 to 59 years and 20% of women aged 60 to 69 years were reported to have osteoporosis (very low BMD) in 1995, 9 and the overall prevalence of osteoporosis in women aged 50 years or older decreased by 2006. 10 Because of these low prevalence rates, identification of osteoporosis in younger postmenopausal women is challenging. Clinical practice guidelines typically encourage BMD screening in postmenopausal women younger than 65 years according to their risk factors for fracture, 2, 3 but there is no agreement regarding which factors to choose from lists of up to 90 predictors. Unlike most clinical screening guidelines for chronic diseases, BMD screening guidelines do not specify a standard testing interval. Younger postmenopausal women without extra risk factors for BMD loss may question whether routine (repeated) BMD testing should be performed soon after the onset of menopause or whether this test can safely be deferred. 11 For younger postmenopausal women and their primary care providers, age-defined data are essential to shared decision-making regarding the timing of BMD tests.
For women older than 65 years, estimated time to osteoporosis is a useful metric for deciding on a BMD screening interval because of known significant fracture rates in this age range of women. 12 In contrast, estimated time to fracture must inform the frequency of BMD screening in younger postmenopausal women because their fracture rates may be low despite transitory accelerated BMD loss immediately after the onset of menopause. 13 In women aged 50 to 54 years, the estimated 5-year risk is 0.2% for first spine fracture and 0.0% for first hip fracture, compared with 1.5% and 0.8% for the respective risks in women aged 65 to 69 years. 14 At the same time, a large study of postmenopausal women followed for up to 3 years after baseline peripheral (heel, forearm, or finger) BMD measures found that relative risks for fracture were similar in women aged 50 to 59 years compared with older age groups. 15 To thoroughly examine the clinical utility of BMD screening in younger postmenopausal women, we must study those with and without osteoporosis, with adequate follow-up to estimate fracture incidence before age 65 years (when routine BMD testing is recommended).
To characterize the incidence of hip or clinical vertebral fracture in younger postmenopausal women at any baseline BMD level, we conducted competing risk analyses of 4,068 postmenopausal women aged 50 to 64 years without a history of hip or clinical vertebral fracture or osteoporosis treatment, who were followed longitudinally for up to 11 years in the Women's Health Initiative (WHI) bone density cohort. We hypothesized that younger postmenopausal women without osteoporosis (hip and lumbar spine T scores 9j2.50) at baseline would be unlikely to experience a hip or clinical vertebral fracture or other major osteoporotic fractures before age 65 years.
METHODS

Study participants
We studied at baseline 4,068 postmenopausal women (aged 50-64 y) participating in the WHI Observational Study or Clinical Trials (hormone therapy, calcium/vitamin D, and dietary trials) placebo groups who had had at least one dualenergy x-ray absorptiometry (DXA) scan between October 1993 and April 2005 at the Tucson/Phoenix, Pittsburgh, or Birmingham clinical center. BMD was followed for a maximum of 11.2 years whereas fracture was followed for a maximum of 18.6 years in the analytical cohort as a whole. Because the competing risk framework requires concurrent follow-up of the primary endpoint (hip or clinical vertebral fracture) and competing risks (including BMD measurements), the effective maximal length of follow-up for the analyses of time to fracture was 11.2 years. However, data from the full period of fracture follow-up (18.6 y) were tabulated in a separate analysis.
Women with any BMD T score at baseline (including osteoporosis) were included in competing risk analyses. Details of study examinations and selection of the analytical cohort are described in Supplemental Digital Content 1 (http://links.lww.com/MENO/A121) and Figure 1 . The study protocol and consent forms for the WHI study were approved by the Institutional Review Boards of all participating institutions. The analysis protocol was reviewed and approved by the Institutional Review Board of the University of North Carolina.
BMD classifications and definition of osteoporosis
Eligible participants had DXA BMD measurements at the femoral neck, total hip, and lumbar spine at one or more study examinations. World Health Organization diagnostic criteria 16 for osteoporosis were used to classify participants by their baseline BMD T scores ([BMD of participant j mean BMD of reference population] / SD of BMD of reference population) at the femoral neck, total hip, or lumbar spine. T scores were calculated using National Health and Nutrition Examination Survey III BMD norms for non-Hispanic white women aged 20 to 29 years. 17, 18 Data from participants without osteoporosis (femoral neck, total hip, and lumbar spine T scores 9j2.50) and with osteoporosis (lowest T score ej2.50) were analyzed separately. We emphasized BMD screening in this study because numerous randomized trials 19<22 have demonstrated the benefit of pharmacologic treatment for postmenopausal women who have osteoporosis (as defined by BMD criteria) and because the US Preventive Services Task Force 1,23 has rigorously reviewed the magnitude of benefits, harms, and net benefit of the use of DXA BMD screening in postmenopausal women.
Outcomes
The primary outcome was the estimated time interval for 1% of participants in three age groups to transition from baseline T-score categories to hip or clinical vertebral fracture before developing osteoporosis (for those without osteoporosis at baseline), before initiating osteoporosis treatment, and before dying. The secondary outcome was the time for 3% of women in each age group to have a major osteoporotic fracture (includes hip, clinical vertebral, proximal humerus, or wrist fracture according to the World Health Organization definition). 24 Fractures were verified via review of radiology, magnetic resonance imaging, or operative reports by centrally trained physician adjudicators at each of the BMD clinics participating in the WHI. For fracture sites other than hip, local clinic physician-adjudicated fractures were used. Final adjudication of hip fractures was performed centrally by blinded WHI physician adjudicators. The agreement between central and local adjudication for hip fracture was 94%. Additional details regarding fracture adjudication are included in Supplemental Digital Content 1 (http://links.lww.com/MENO/A121).
Independent variables
Demographics and prevalence of risk factors for osteoporosis and fracture were tabulated. Regression models for occurrence of fracture in women without osteoporosis at baseline were adjusted for baseline age group (50-54, 55-59, and 60-64 y), continuous T score (centered at the mean of the lowest T score at any site for each individual without osteoporosis at baseline), body mass index, race/ethnicity (black [referent] vs nonblackYnonwhite vs white), and current hormone therapy use status at baseline. The regression model for women with osteoporosis at baseline was adjusted only for age (centered at the mean age of women with baseline osteoporosis).
Medication use
Use of Food and Drug AdministrationYapproved agents for osteoporosis treatment (bisphosphonates including alendronate, risedronate, pamidronate, or zoledronate; calcitonin; raloxifene; and parathyroid hormone) was assessed in the WHI Observational Study and WHI Extension Hormone Use Update FIG. 1. Study population for analyses of time to hip or clinical vertebral fracture. Of the 4,527 women who had dual-energy x-ray absorptiometry (DXA) bone mineral density (BMD) testing, 459 were excluded, including those who had had a hip or clinical vertebral fracture or osteoporosis treatment (bisphosphonate or calcitonin) at their first study examination, and those who did not have BMD measurements at two or more examinations, or those who had one BMD measurement and subsequent development of a competing risk. In the analytical cohort of 4,068 women with adequate femoral neck, total hip, and lumbar spine BMD measurements before censoring, two transitions were studied: T scores higher than j2.50 for transition to first hip or clinical vertebral fracture (n = 3,724) and T scores of j2.50 or lower for transition to first hip or clinical vertebral fracture (n = 344). medication follow-up surveys (for survey questions, see Supplemental Digital Content 1, http://links.lww.com/MENO/A121). Osteoporosis treatment agents were prescribed by the participants' doctors, not by WHI study personnel. Participants were asked to report any use of the individual agents in the past year. The exact length of therapy was unknown.
Statistical analysis
Competing risk analyses were conducted in each age group to estimate the cumulative incidence functions for time to development of hip or clinical vertebral fracture and the corresponding intervals for 1% of participants to transition to fracture. The competing risks were development of osteoporosis (for women without osteoporosis at baseline), initiation of a Food and Drug AdministrationYapproved agent for osteoporosis treatment, and death. The time origin was the first study visit including BMD measurements at all three anatomical sites (femoral neck, total hip, and lumbar spine), with follow-up continuing until the study examination preceding death or dropout. Parametric regression models 25 were fitted to the cumulative incidence of fracture using naBve maximum likelihood analysis. The 1% time intervals and associated CIs were based on the competing risk quantile methodology, 26 as implemented by Lee and Fine 27 for parametric models. Similar competing risk models were constructed to estimate the time for 3% of women in each age group to have a major osteoporotic fracture. Technical details are provided in Supplemental Digital Content 1 (http://links.lww.com/MENO/A121).
The very small number of major fracture events precluded use of competing risk regression analysis to estimate time to fracture, adjusting for additional clinical risk factors beyond those listed above. We instead used Fisher's exact test to compare the crude number of participants with and without osteoporosis at baseline who had a hip or clinical vertebral fracture after their baseline visit, cross-tabulated with key categorical risk factors described in BIndependent Variables.[ Because concurrent BMD and fracture follow-up was not required, we used the full amount of fracture follow-up data (during a maximum of 18.6 y) and included all hip and clinical vertebral fractures whether or not they occurred before a competing risk. For this reason, the total number of fractures was greater in Fisher's exact test analyses than in competing risk analyses.
All analyses were performed using Statistical Analysis Software version 9.3. 28
RESULTS
Characteristics of the analytical cohort
Baseline characteristics of the analytical cohort are shown in Table 1 . Tabulations of osteoporosis according to three different definitions ( Table 2; Supplement Tables A2, A3 , Supplemental Digital Content 1, http://links.lww.com/MENO/A121) revealed that 51% (170 of 344) of osteoporosis diagnoses were determined by lumbar spine BMD measurement (lumbar spine T score ej2.50; femoral neck and total hip T scores 9j2.50).
Estimated time to hip or clinical vertebral fracture
The following proportions of women (including those with osteoporosis at baseline) sustained a hip or clinical vertebral fracture before initiating osteoporosis treatment: aged 50 to 54 years at baseline, 12 of 1,069 (1.1%); aged 55 to 59 years at baseline, 24 of 1,391 (1.7%); aged 60 to 64 years at baseline, 37 of 1,608 (2.3%); all ages, 73 of 4,068 (1.8%).
Unadjusted (Fig. 2 ) and covariate-adjusted estimates of the cumulative incidence of first hip or clinical vertebral fracture as a function of testing interval length were similar. The adjusted estimated times for 1% of women without osteoporosis to transition to hip or clinical vertebral fracture decreased with increasing age (Table 3) , ranging from 12.8 years (95% CI, 8.0-20.4) for women aged 50 to 54 years to 11.7 years (95% CI, 6.9-20.0) for women aged 55 to 59 years to 7.6 years (95% CI, 4.8-12.1) for women aged 60 to 64 years. For those with osteoporosis, the age-adjusted time interval was 3.0 years (95% CI, 1.3-7.1) for women aged 50 to 64 years analyzed together.
The crude proportion (not accounting for competing risks) of participants who had at least one hip or clinical vertebral fracture by the end of follow-up was significantly higher for women with osteoporosis than for women without osteoporosis at baseline in all subgroups of age, body mass index, personal fracture history, parental history of hip fracture, smoking, and hormone therapy use ( Table 4 ). Tabulations of primary endpoint and competing risk events ( Table 2) showed that treatment was the first event for 673 women (16.5% of the analytical cohort), that is, 531 (13.1% of the analytical cohort) participants without osteoporosis at baseline were treated before they developed osteoporosis or before they had a hip or clinical vertebral fracture, and 142 (3.5% of the analytical cohort) women with baseline osteoporosis were treated before they had a hip or clinical vertebral fracture.
Estimated time to major osteoporotic fracture
These proportions of women (including those with osteoporosis at baseline) sustained a major osteoporotic fracture before initiating osteoporosis treatment: aged 50 to 54 years at baseline, 38 of 1,069 (3.6%); aged 55 to 59 years at baseline, 71 of 1,391 (5.1%); aged 60 to 64 years at baseline, 93 of 1,608 (5.8%); all ages, 202 of 4,068 (5.0%).
The estimated times for 3% of women without baseline osteoporosis to have a major osteoporotic fracture (hip, clinical vertebral, proximal humerus, or wrist) ranged from 11.5 years (95% CI, 8.0-16.7) for women aged 50 to 54 years to 8.6 years (95% CI, 5.8-12.8) for women aged 60 to 64 years at baseline ( Table 5) .
For all women aged 50 to 64 years with baseline osteoporosis analyzed together, the age-adjusted time for 3% of women to have a major osteoporotic fracture was 2.5 years (95% CI, 1.2-5.3) (event, 31 of 344 [9.0%]). The proportions of women with baseline osteoporosis who had a major osteoporotic fracture before initiating treatment were as follows: 3 of 40 (7.5%) for women aged 50 to 54 years; 10 of 106 (9.43%) for women aged 55 to 59 years; and 18 of 198 (9.1%) for women aged 60 to 64 years. Within these groups, three, seven, and nine women respectively had a major osteoporotic fracture before age 65 years.
DISCUSSION
This longitudinal study found that, among postmenopausal women aged 50 to 64 years without osteoporosis on their first BMD test, less than 1% experienced a hip or clinical vertebral fracture and less than 3% experienced a major osteoporotic fracture by 7 years. The analysis accounted for different clinical trajectories (ie, incident osteoporosis, death, or initiation of treatment before a first major osteoporotic fracture was modeled as a competing risk). Our results suggest that younger postmenopausal women without osteoporosis on their first BMD scan are unlikely to benefit from frequent rescreening before age 65 years. Adjustment for several clinical risk factors for fracture did not substantially alter these findings. Women with osteoporosis on their first BMD test (8.5% of the cohort) had a significantly higher risk of fracture before age 65 years than women without osteoporosis. Empirical data on age-appropriate osteoporosis screening are important because of substantial underutilization of BMD testing in women aged 65 years or older 29 and inappropriate use in other postmenopausal women who do not meet screening criteria in published clinical practice guidelines. 30 In 2011, the National Physicians Alliance initiated a project titled BPromoting Good Stewardship in Clinical Practice[ that aimed to develop a list of the top five activities in family medicine, internal medicine, and pediatrics where quality of care could be improved. 31 This list included the recommendation, Bdon't use DEXA screening for osteoporosis in women under age 65 years or men under 70 years with no risk factors,[ citing the lack of cost-effectiveness in these groups. Although the project's focus on cost control was understandable, the BMD testing recommendations were not based on original studies testing this hypothesis. Our results substantiate that DXA BMD testing has a lower yield for younger postmenopausal women than for women aged 65 years or older. However, because hip and spine fractures would be catastrophic for working adult women who are otherwise healthy, we do not interpret our results to mean that no postmenopausal women younger than 65 years should have a DXA test. Instead, the data suggest that postmenopausal women would be unlikely to have a major fracture before age 65 years, but development of osteoporosis by BMD criteria remains important because it confers a higher immediate risk of major fracture compared with greater BMD levels. Our results are generalizable to younger postmenopausal women with good general health who are candidates for BMD screening in primary care practice. Our results should not be applied to individuals with existing fragility fractures or secondary causes of osteoporosis who are seen in subspecialty clinics or to individuals who have taken antifracture treatment agents. Those individuals are no longer candidates for screening because they have higher baseline risk for subsequent fractures and thereby different testing and treatment criteria.
Current clinical practice guidelines encourage the use of risk factors for fracture to select postmenopausal women younger than 65 years who are good candidates for DXA testing. 1, 2 Two analyses of large cohorts of postmenopausal women aged 50 to 64 years at baseline suggest that simple fracture risk assessment tools (including one calculated from age and weight) perform as well as more complicated tools for this purpose. 32, 33 Our data can help inform a BMD testing interval for postmenopausal women who are screened before age 65 years. Using the more conservative time estimates for major osteoporotic fracture, clinicians might allow women aged 50 and 54 years without osteoporosis on their first BMD test to wait 10 years for their next test. Similarly, women aged 60 to 64 years without osteoporosis on their first BMD test might wait until after age 65 years for their next test. Other approaches have been considered. For example, Reid and Gamble's 34 modeling study based on doubling time for predicted hip fracture risk suggested that a BMD screening interval of 5 to 6 years may be appropriate for many intermediate-risk women aged 65 years or older. This 5-to-6-year interval might be interpreted as a conservative estimate for intermediate-risk younger postmenopausal women.
Women found to have osteoporosis in this age range are no longer candidates for a routine screening schedule. We included these women in the analysis because if they had osteoporosis but did not sustain a fracture until well after age 65 years, the value of any BMD screening before age 65 years would be questioned. Instead, we found that all (3 of 3) of the women aged 50 to 54 years and more than half (16 of 28) of women aged 55 to 64 years with baseline osteoporosis who had a major osteoporotic fracture during follow-up had the fracture before age 65 years. This suggests that clinicians should promptly counsel younger postmenopausal women with osteoporosis regarding the benefits and harms of treatment, rather than assuming that this discussion can be deferred. Although women with osteoporosis had a substantially higher risk of fracture, most of the hip and clinical vertebral fractures in the cohort as a whole occurred in women with baseline T scores higher than j2.50 (ie, 65 of 3,724 [1.7%] women with baseline T scores 9j2.50 vs 25 of 344 [7.3%] women with baseline T scores ej2.50 had a hip or clinical vertebral fracture). These results are consistent with other longitudinal studies of postmenopausal women 35, 36 and demonstrate that BMD testing cannot identify every individual who will have a future fragility fracture. Such findings emphasize the importance of further investigations of risk factor assessment and screening methods to identify poor bone quality that also contributes to increased fracture risk.
According to current clinical practice guidelines, 2,5,8 women with asymptomatic radiographic vertebral fractures should also receive osteoporosis treatment regardless of BMD T-score level. Radiographic vertebral fracture data were not available in the WHI study, but a US populationYbased study reported very low vertebral fracture incidence rates for this age range of women (215-349 per 100,000 [0.35%] women aged 50-64 y). 37 Considering that one third or fewer of incident radiographically identified vertebral fractures are clinically diagnosed, clinicians may consider additional imaging (lateral thoracic and lumbar spine radiographs or densitometric vertebral fracture assessment imaging) in postmenopausal women with BMD T scores between j1.5 and j2.4 who demonstrate height loss or other risk factors that may suggest prevalent radiographic vertebral fracture. 38 The low incidence rates of hip or clinical vertebral fractures in our analysis are consistent with the 2008 Cochrane review of alendronate treatment, which showed very low absolute risk reductions (ARRs) for hip and clinical vertebral fractures in younger postmenopausal women. Women aged 50 to 54 years who were treated with alendronate had 5-year ARRs of 0.1% for first spine fracture and 0.0% for first hip fracture, with analogous figures of 0.5% and 0.1% for women aged 60 to 64 years and 0.7% and 0.4% for women aged 65 to 69 years. 19 In contrast, the ARR for alendronate-treated women aged 90 years or older was 11.1% for spine fracture and 2.1% for hip fracture. The very low treatment efficacy of alendronate in younger women was probably attributable to their low baseline (untreated) fracture rates, such that treatments did not confer a significant absolute fracture risk reduction. Because of these low fracture rates, BMD screening and treatment in younger postmenopausal women are likely to have less of an impact on the population burden of fracture compared with screening and treatment in women aged 65 years or older. Careful selection of women for screening and treatment is especially important before age 65 years because the risk of complications, such as atypical femoral fractures 39 and osteonecrosis of the jaw, 40 seems to rise with increasing duration of exposure to bisphosphonates. The 3% fracture threshold used in our analysis of major osteoporotic fractures was much lower than the 20% estimated fracture risk threshold for which treatment may be recommended according to the World Health Organization FRAX fracture risk algorithm. 24 Thus, our time estimates for the major osteoporotic fracture endpoint should not be viewed as an estimated time until treatment initiation.
Our study had several limitations. Our time estimates were based only on transitions to major fracture; the full benefits and risks of screening and cost-effectiveness were not considered. The analysis had inadequate power to study fracture risk in subgroups defined by individual risk factors. For example, a higher proportion of women with osteoporosis and current hormone therapy use at baseline had a hip or clinical vertebral fracture during follow-up compared to women with osteoporosis and without current hormone therapy use at baseline. This might have represented confounding by treatment indication or mere variability in an estimate based on very few fracture events. More than 97% of the original WHI participants were not eligible for this analysis because they were not part of the BMD cohort. However, our study population included 89.9% (4,068 of 4,527) of the WHI participants with technically adequate BMD measurements at one or more study examinations. Seventy-four percent of our sample comprised white women, and 15% comprised black women; because the prevalence of hip osteoporosis in white women is lower than the prevalence of hip osteoporosis in African-American women by National Health and Nutrition Examination Survey estimates, 10 our calculated estimates of time to major fracture are likely to be reasonable estimates for women of all races. Because of rare fracture events in lowest-risk women, some of our time estimates were extrapolations with wide CIs. Strengths of the analysis include the large size of the cohort and the long follow-up period involving repeated BMD testing, fracture ascertainment between study visits, inclusion of the lumbar spine in BMD measurements, and inclusion of mortality as a competing risk.
CONCLUSIONS
Postmenopausal women aged 50 to 64 years without osteoporosis on their first BMD test are very unlikely to have a major osteoporotic fracture before age 65 years. Although less than 10% of our cohort had osteoporosis at baseline, the osteoporosis subgroup had a significantly higher immediate risk of major fracture. Screening frequency should be based on age and baseline T score to maximize the clinical utility of BMD testing in this age range.
